Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

23.67 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Jun 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026? ↗

June 25, 2026

AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.

Via The Motley Fool

Topics Intellectual Property

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? ↗

June 25, 2026

Novo Nordisk is no longer the front-runner, but it's not out of the running, either.

Via The Motley Fool

FDA Expands Pfizer's Ibrance Label For Frontline Maintenance In Advanced Breast Cancer ↗

June 25, 2026

The FDA approves Pfizer's Ibrance regimen for HR+, HER2+ metastatic breast cancer maintenance after positive Phase 3 data.

Via Benzinga

Most active S&P500 stocks in Wednesday's session ↗

June 24, 2026

Via Chartmill

2 Large-Cap Stocks to Target This Week and 1 We Find Risky

June 25, 2026

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

Via StockStory

Pfizer Declares Third-Quarter 2026 Dividend

June 24, 2026

From Pfizer Inc.

Via Business Wire

The Highest Dividend Yields Are Often the Least Safe. Here's How to Tell the Difference. ↗

June 24, 2026

Income investors are drawn to the biggest yields, but the biggest yields frequently belong to the companies the market trusts least. A yield is simply the

Via Talk Markets

FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

June 24, 2026

From Pfizer Inc.

Via Business Wire

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

June 24, 2026

Via Investor Brand Network

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies

June 24, 2026

Via Investor Brand Network

Topics Artificial Intelligence

Pfizer Stock Trades Flat Following Mixed Phase 3 Lung Cancer Trial Data ↗

June 24, 2026

Pfizer shares are trading flat in Wednesday's premarket as traders weigh mixed Phase 3 trial headlines alongside a firmer overnight tape.

Via Benzinga

2 High-Yield Dividend Stocks to Buy and Hold for a Decade ↗

June 23, 2026

Don't wait until they recover to initiate positions.

Via The Motley Fool

Topics Artificial Intelligence Economy Initial Public Offering

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

June 24, 2026

From BioMedWire

Via GlobeNewswire

Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗

June 23, 2026

Via Chartmill

Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients ↗

June 23, 2026

Pfizer's sigvotatug vedotin missed its Phase 3 OS goal in NSCLC but showed encouraging results in second-line patients.

Via Benzinga

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

June 23, 2026

From Pfizer Inc.

Via Business Wire

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

June 22, 2026

From Pfizer Inc.

Via Business Wire

Pfizer Stock Edges Lower Monday: What's Going On? ↗

June 22, 2026

Pfizer shares are trading lower by about half a percent on Monday as investors digest a leadership transition in the finance seat.

Via Benzinga

GEA Group Aktiengesellschaft Targets EUR 7B Revenue, Higher Margins by 2030 ↗

June 22, 2026

GEA Group Aktiengesellschaft (ETR:G1A) outlined its 2030 growth and profitability targets during an Industrial Technology Conference presentation, with Investor Relations Manager Eduard Biller saying...

Via MarketBeat

Topics Supply Chain

Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This Instead ↗

June 22, 2026

The healthcare company is eyeing opportunities related to artificial intelligence, which it believes can enhance its operations.

Via The Motley Fool

Topics Artificial Intelligence Earnings Intellectual Property

GLP-1 Receptor Agonist Market Revenue Analysis Across Key Regions ↗

June 22, 2026

The global GLP-1 Receptor Agonist Market was valued at USD 66.4 billion in 2025 and is projected to grow from USD 82.0 billion in 2026 to USD 185.3 billion

Via Talk Markets

2 Reasons to Like ZTS and 1 to Stay Skeptical

June 22, 2026

Zoetis has gotten torched over the last six months - since December 2025, its stock price has dropped 36.6% to $78.46 per share. This was partly driven by it...

Via StockStory

Could Pfizer Stock Be Your Ticket to Generational Wealth? ↗

June 21, 2026

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

Via The Motley Fool

Topics Intellectual Property

Want to Retire on $500,000? 3 Stocks to Buy and Never Sell ↗

June 21, 2026

These dividend stocks could help make retiring on $500,000 a real possibility.

Via The Motley Fool

Topics Artificial Intelligence Retirement

Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors? ↗

June 20, 2026

Pfizer is out of favor right now, and for good reason, but dividend investors may want to take the risk just the same.

Via The Motley Fool

Topics Intellectual Property

Apple's Price Warning Sends Memory Chips To A Record, Accenture Cracks 18% ↗

June 19, 2026

Via Chartmill

Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook ↗

June 18, 2026

Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.

Via The Motley Fool

Topics Intellectual Property Stocks

Thursday's session: most active stock in the S&P500 index ↗

June 18, 2026

Via Chartmill

These S&P500 stocks have an unusual volume in today's session ↗

June 18, 2026

Via Chartmill

Pfizer Stock Drops Today As CFO Steps Down In August ↗

June 18, 2026

Pfizer shares are slipping Thursday after it announced that Chief Financial Officer Dave Denton will leave the organization.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.